Abstract
Tumor antigenic peptides therapeutics is a promising field for cancer immunotherapy; advantages include convenient synthesis and modification of antigenic peptides, as well as little toxicity associated with its administration. Vaccination of the peptides derived from tumor-associated antigen (TAA) was specifically designed for T cells in the context of MHC molecules. In the past decades, tumor antigenic peptides have been examined in clinic but numbered success has been obtained because of the stability of peptide and delivery approaches, consequently leading to an inefficient antigen presentation and low response rates in cancer patients. Thus, the appropriate and efficient peptide vaccine carrier systems still continue to be a major obstacle. However, both sipuleucel-T vaccine and anti-CTLA-4 antibody have been approved by FDA for the treatment of metastatic prostate cancer and melanoma, respectively. PLGA has been recently used as the adjuvant to elicit enhanced immune responses while delivering tumor antigenic peptides. Intracellular delivery of the peptides derived from TAA into DCs would prolong antigen presentation of APC to T cells. This article aims to describe a new delivery method regarding tumor antigenic peptides and rationales of DCs-based vaccination.
Keywords: Antigen-presenting cells (APC), cancer immunotherapy, cytotoxic T lymphocytes (CTL), dendritic cells (DCs), PLGA-nanoparticle (PLGA-NPs), peptide, tumor-associated antigen (TAA).
Current Medicinal Chemistry
Title:Intracellular Delivery of Tumor Antigenic Peptides in Biodegradablepolymer Adjuvant for Enhancing Cancer Immunotherapy
Volume: 21 Issue: 21
Author(s): H. Li and W. Ma
Affiliation:
Keywords: Antigen-presenting cells (APC), cancer immunotherapy, cytotoxic T lymphocytes (CTL), dendritic cells (DCs), PLGA-nanoparticle (PLGA-NPs), peptide, tumor-associated antigen (TAA).
Abstract: Tumor antigenic peptides therapeutics is a promising field for cancer immunotherapy; advantages include convenient synthesis and modification of antigenic peptides, as well as little toxicity associated with its administration. Vaccination of the peptides derived from tumor-associated antigen (TAA) was specifically designed for T cells in the context of MHC molecules. In the past decades, tumor antigenic peptides have been examined in clinic but numbered success has been obtained because of the stability of peptide and delivery approaches, consequently leading to an inefficient antigen presentation and low response rates in cancer patients. Thus, the appropriate and efficient peptide vaccine carrier systems still continue to be a major obstacle. However, both sipuleucel-T vaccine and anti-CTLA-4 antibody have been approved by FDA for the treatment of metastatic prostate cancer and melanoma, respectively. PLGA has been recently used as the adjuvant to elicit enhanced immune responses while delivering tumor antigenic peptides. Intracellular delivery of the peptides derived from TAA into DCs would prolong antigen presentation of APC to T cells. This article aims to describe a new delivery method regarding tumor antigenic peptides and rationales of DCs-based vaccination.
Export Options
About this article
Cite this article as:
Li H. and Ma W., Intracellular Delivery of Tumor Antigenic Peptides in Biodegradablepolymer Adjuvant for Enhancing Cancer Immunotherapy, Current Medicinal Chemistry 2014; 21 (21) . https://dx.doi.org/10.2174/092986732121140521100224
DOI https://dx.doi.org/10.2174/092986732121140521100224 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Sodium Carbonate Sesquiperhydrate (2Na2CO3-3H2O2) Catalysed One-pot Synthesis of Biologically Dynamic Novel Substituted Spirooxirane Dicarboxamides
Current Catalysis Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Editorial [Hot Topic: Novel Kinase Inhibitors in Cancer Therapy (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection <i>via</i> Microarray Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Current Drug Targets Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Development and Evaluation of Ropivacaine Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres with Low Burst Release
Current Drug Delivery Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future
Infectious Disorders - Drug Targets Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Deubiquitinating Enzymes: Their Functions and Substrate Specificity
Current Protein & Peptide Science Novel Integrin-Specific Targets for Anti-Platelet Therapies
Current Pharmaceutical Design